Suppr超能文献

内镜切除术后辅以适当的附加治疗,浸润深度病理 T1a-黏膜肌层和 T1b-黏膜下层的食管鳞状细胞癌的长期预后。

Long-term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1a-muscularis mucosae and T1b-submucosa by endoscopic resection followed by appropriate additional treatment.

机构信息

Department of, Gastroenterology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.

出版信息

Dig Endosc. 2022 May;34(4):793-804. doi: 10.1111/den.14154. Epub 2021 Oct 20.

Abstract

OBJECTIVES

Endoscopic resection (ER) is indicated for a wide range of superficial esophageal squamous cell carcinomas (ESCCs). We examined the long-term outcomes in patients with pathological (p) invasion of ESCC into the T1a-muscularis mucosae (MM) and T1b-submucosa (SM) after ER, for which data on prognosis are limited.

METHODS

Of the 1217 patients with superficial ESCC who underwent ER, 225 patients with a pathological diagnosis of ESCC invasion into the MM, minute submucosal invasion ≤200 µm (SM1), or massive submucosal invasion (SM2) were included. In patients with lymphovascular invasion, droplet infiltration, or SM2 invasion, additional treatments, including chemoradiation (CRT) or esophagectomy with two- to three-field lymph node dissection, were recommended. The median observation period was 66 months (interquartile range 48-91 months).

RESULTS

In total, there were 151, 28, and 46 pT1a-MM, pT1b-SM1, and pT1b-SM2 cases, respectively. Metastatic recurrence was observed in 1.3%, 10.7%, and 6.5% patients with pT1a-MM, pT1b-SM1, and pT1b-SM2 ESCCs, respectively. Of the eight patients with metastatic recurrence, six were successfully treated, and two died of ESCC. The 5-year overall survival rates were 84.1%, 71.4%, and 67.4%, the 5-year relapse-free survival rates were 82.8%, 64.3%, and 65.2%, and the 5-year disease-specific survival rates were 100%, 96.4%, and 99.1% in patients with pT1a-MM, pT1b-SM1, and pT1b-SM2 ESCCs, respectively. Multivariate analysis showed that additional CRT and esophagectomy, and T1b-SM2 were positively and negatively associated with overall survival, respectively.

CONCLUSIONS

Endoscopic resection preceding appropriate additional treatments resulted in favorable outcomes. Many cases of metastatic recurrence in this cohort could be successfully treated.

摘要

目的

内镜下切除(ER)适用于广泛的食管鳞状细胞癌(ESCC)浅层病变。我们检查了接受 ER 治疗后病理(p)侵犯食管 T1a-黏膜肌层(MM)和 T1b-黏膜下层(SM)的 ESCC 患者的长期预后,这方面的预后数据有限。

方法

在 1217 例接受 ER 治疗的浅层 ESCC 患者中,纳入 225 例病理诊断为 MM 侵犯、微小黏膜下侵犯(SM1)≤200µm 或广泛黏膜下侵犯(SM2)的 ESCC 患者。对于有淋巴管血管侵犯、微浸润或 SM2 侵犯的患者,建议进行额外的治疗,包括放化疗(CRT)或两到三野淋巴结清扫的食管癌切除术。中位观察期为 66 个月(四分位间距 48-91 个月)。

结果

共有 151、28 和 46 例 pT1a-MM、pT1b-SM1 和 pT1b-SM2 患者。pT1a-MM、pT1b-SM1 和 pT1b-SM2 患者的转移性复发率分别为 1.3%、10.7%和 6.5%。8 例转移复发患者中,6 例成功治疗,2 例死于 ESCC。pT1a-MM、pT1b-SM1 和 pT1b-SM2 ESCC 患者的 5 年总生存率分别为 84.1%、71.4%和 67.4%,5 年无复发生存率分别为 82.8%、64.3%和 65.2%,5 年疾病特异性生存率分别为 100%、96.4%和 99.1%。多因素分析显示,额外的 CRT 和食管癌切除术以及 T1b-SM2 与总生存率呈正相关和负相关。

结论

内镜下切除加适当的辅助治疗可获得良好的效果。该队列中许多转移性复发的病例可以成功治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验